Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?

Transplantation

Volumn 89, Issue 10, 2010, Pages 1218-1223

  McGillicuddy, John W ^a   Weimert, Nicole A ^b,c   Taber, David J ^b,c   Turner, Annie ^a   Mitchell, Larrissa A ^a   Wray, Dannah W ^a   Egidi, Maria F ^a   Kuppachi, Sarat ^a   Hughes, Michael G ^a   Baliga, Prabhakar K ^a   Chavin, Kenneth D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

CMV; Prophylaxis; Renal; Transplant

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; INTERMETHOD COMPARISON; KIDNEY PANCREAS TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; TREATMENT DURATION; VIRAL RESPIRATORY TRACT INFECTION; VIREMIA;

ACYCLOVIR; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PATIENT SELECTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 77952885189     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d54ba6     Document Type: Article

References (14)

1. Legendre C, Pascual M. Improving outcomes for solid-organ transplant at risk from cytomegalovirus infection: Late-onset disease and indirect consequences. Clin Infect Dis 2008; 46: 732.
2. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
3. Baillie GM. Preventionof cytomegalovirus disease in solid organ transplant patients: Prophylactic versus preemptive therapy. Am J Health Syst Pharm 2006; 63(19 suppl 5): S10.
4. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the managementof cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
5. Miller GG, Kaplan B. Prophylaxis versus preemptive protocols for CMV: Do they impact graft survival? Am J Transplant 2008; 8: 913.
6. Von Müller L, Hampl W, Hinz J, et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40: 2285. Available at: http://www.fda.gov/medwaTCH/SAFETY/2003/valcyte- pi.pdf. [accessed January 20, 2009].
7. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
8. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria\An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
9. Byford S, Raftery J. Perspectives in economic evaluation. BMJ 1998; 316: 1529.
10. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganci-clovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
11. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
12. Reischig T, Jindra P, Hes O, et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009; 87: 436.
13. Sadeghi M, Daniel V, Naujokat C, et al. Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation 2008; 86: 275.
14. Balfour HH Jr, Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomeg-alovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381.